Patents Assigned to STEMRIM INC.
-
Patent number: 11969459Abstract: The present inventors have found that HMGB1 fragment peptides having a particular amino acid sequence exhibit the effects of improvement of cardiac function, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of dilated cardiomyopathy, that the particular HMGB1 fragment peptides also exhibit the effects of improvement of cardiac function, inhibition of cardiomegaly, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of ischemic cardiomyopathy caused by old myocardial infarction, and that the particular HMGB1 fragment peptides exhibit the effects of inhibition of cardiomyocyte hypertrophy and inhibition of myocardial fibrosis in an animal model of hypertensive cardiomyopathy.Type: GrantFiled: January 26, 2018Date of Patent: April 30, 2024Assignees: StemRIM Inc., OSAKA UNIVERSITYInventors: Katsuto Tamai, Yoshiki Sawa, Shigeru Miyagawa, Takashi Kido, Takasumi Goto, Takehiko Yamazaki
-
Publication number: 20240050481Abstract: The present disclosure includes a composition for use in the treatment of dystrophic epidermolysis bullosa, comprising a blister-derived cell of a patient with dystrophic epidermolysis bullosa that is genetically modified to produce type VII collagen.Type: ApplicationFiled: July 21, 2021Publication date: February 15, 2024Applicants: OSAKA UNIVERSITY, STEMRIM INC.Inventors: Katsuto TAMAI, Yasushi KIKUCHI, Tomoki TAMAKOSHI, Takehiko YAMAZAKI
-
Patent number: 11826401Abstract: The present inventors have found that HMGB1 fragment peptides having a particular amino acid sequence exhibit the effects of improvement of cardiac function, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of dilated cardiomyopathy, that the particular HMGB1 fragment peptides also exhibit the effects of improvement of cardiac function, inhibition of cardiomegaly, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of ischemic cardiomyopathy caused by old myocardial infarction, and that the particular HMGB1 fragment peptides exhibit the effects of inhibition of cardiomyocyte hypertrophy and inhibition of myocardial fibrosis in an animal model of hypertensive cardiomyopathy.Type: GrantFiled: January 26, 2018Date of Patent: November 28, 2023Assignees: STEMRIM INC., OSAKA UNIVERSITYInventors: Katsuto Tamai, Yoshiki Sawa, Shigeru Miyagawa, Takashi Kido, Takasumi Goto, Takehiko Yamazaki
-
Publication number: 20230173027Abstract: A pharmaceutical composition containing the substance according to any one of the following (a) to (c), an organic acid, a metal salt of an organic acid, and a sugar and/or a sugar alcohol, wherein when the pharmaceutical composition is dissolved in distilled water for injection, a pH of the pharmaceutical composition is 3.0 to 4.Type: ApplicationFiled: April 19, 2021Publication date: June 8, 2023Applicants: Shionogi & Co., Ltd., StemRim Inc.Inventors: Nao MATSUOKA, Shuichi HATANO, Yuya KUGA, Maki OKABE, Takehiko YAMAZAKI, Koichi YOKOTA
-
Publication number: 20220265787Abstract: The present disclosure includes a composition for promoting growth or suppressing decrease of mesenchymal stem cells comprising serpin A3.Type: ApplicationFiled: July 30, 2020Publication date: August 25, 2022Applicants: STEMRIM INC., OSAKA UNIVERSITYInventors: Katsuto TAMAI, Takashi SHIMBO, Takehiko YAMAZAKI
-
Patent number: 11298403Abstract: The present inventors discovered that an HMGB1 fragment peptide having a specific amino acid sequence exhibits an effect of suppressing weight loss and an effect of suppressing shortening of the large intestine and mucosal damage in an animal model of inflammatory bowel diseases. Based on these findings, pharmaceutical compositions for the prevention and/or treatment of inflammatory bowel diseases, which comprise the HMGB1 fragment peptide having the specific amino acid sequence are provided.Type: GrantFiled: November 30, 2018Date of Patent: April 12, 2022Assignees: STEMRIM INC., OSAKA UNIVERSITYInventors: Katsuto Tamai, Takashi Shimbo, Takehiko Yamazaki
-
Publication number: 20210386823Abstract: The inventors of the present invention searched for a substance that is effective in treating a cartilage disorder, and as a result, found that, in an animal model of joint cartilage deficiency, an HMGB1 fragment peptide having a specific amino acid sequence exhibits the effect of reproducing a healthy cartilage tissue including a hyaline cartilage. Based on this finding, the present invention provides a pharmaceutical composition that contains the specific HMGB1 fragment peptide and that is for preventing and/or treating a cartilage disorder.Type: ApplicationFiled: October 25, 2019Publication date: December 16, 2021Applicants: OSAKA UNIVERSITY, STEMRIM INC.Inventors: Katsuto TAMAI, Takashi SHIMBO, Eiji SASAKI, Takahiro TSUSHIMA, Takehiko YAMAZAKI
-
Patent number: 11197895Abstract: Biologically low invasive vessels are filled with biological factors that have the activity of mobilizing specific functional cells in the body. The vessels are indwelled in the body. After specific functional cells are mobilized into the vessels, the vessels are removed from the body to collect functional cell populations mobilized to the vessels. Alternatively, the cells are directly collected from the vessels indwelled in the body.Type: GrantFiled: August 11, 2017Date of Patent: December 14, 2021Assignees: STEMRIM INC., OSAKA UNIVERSITYInventors: Katsuto Tamai, Takehiko Yamazaki, Takenao Chino, Yasufumi Kaneda
-
Patent number: 11191786Abstract: It was revealed that the intravenous administration of HMGB-1 and S100A8 promoted the healing of skin ulcer by recruiting bone marrow-derived cells to the site of skin ulcer. Furthermore, when HMGB-1 was intravenously administered to cerebral infarction model mice after creation of cerebral infarction, bone marrow-derived cells expressing nerve cell markers were detected in their brain. A marked cerebral infarct-reducing effect was observed in mice intravenously administered with HMGB-1 as compared to the control. The post-cerebral infarction survival rate was increased in the intravenous HMGB-1 administration group. The involvement of bone marrow pluripotent stem cells in the process of bone fracture healing was assessed using mice, and the result demonstrated that bone marrow-derived cells distant from the damaged site migrated to the bone fracture site to repair the damaged tissue.Type: GrantFiled: October 28, 2010Date of Patent: December 7, 2021Assignees: STEMRIM INC., OSAKA UNIVERSITYInventors: Katsuto Tamai, Yasufumi Kaneda, Takehiko Yamazaki, Takenao Chino, Kotaro Saga, Mayumi Endo
-
Publication number: 20210163552Abstract: A peptide which can be utilized as an active ingredient of a composition for use in stimulation of migration of PDGFR?-positive cells, a composition for use in recruitment of bone marrow mesenchymal stem cells from bone marrow to peripheral blood, a composition for use in regeneration of tissues, or a composition for use in stimulation of migration of bone marrow-derived stromal cells is provided.Type: ApplicationFiled: April 24, 2018Publication date: June 3, 2021Applicants: SHIONOGI & CO., LTD., StemRIM Inc.Inventors: Yoichiro NIHASHI, Tomoyuki KAWACHI, Yukiko YAMATSU, Masataka FUMOTO, Takehiko YAMAZAKI
-
Publication number: 20200291359Abstract: The inventors discovered that ectodermal mesenchymal stem cells circulating in peripheral blood that are induced by necrotic tissue damage contribute to the regeneration of damaged tissue. On the basis of this discovery, provided are ectodermal mesenchymal stem cells, a method for producing the same, and a screening method for a substance having pluripotent stem cell inductive activity, the screening method using cells induced by necrotic tissue damage in peripheral blood as an index.Type: ApplicationFiled: November 30, 2018Publication date: September 17, 2020Applicants: STEMRIM INC., OSAKA UNIVERSITYInventors: Katsuto TAMAI, Takashi SHIMBO, Eiji SASAKI, Takehiko YAMAZAKI
-
Patent number: 10550165Abstract: (Objective) An objective of the present invention is to provide therapeutic agents that, in association with stimulation of PDGFR?-positive cells such as bone marrow mesenchymal stem cells, promote their mobilization into blood and accumulation in a damaged tissue, and induce tissue regeneration in a living body. (Means for solution) Multiple peptides were synthesized, and the migration-promoting activity of each peptide was evaluated. As a result, the present inventors successfully identified multiple peptides that have migration-promoting activity on a PDGFR?-positive bone marrow mesenchymal stem cell line (MSC-1). Further, the present inventors confirmed that the identified peptides also have migration-promoting activity on skin fibroblasts, which are PDGFR?-positive cells.Type: GrantFiled: August 30, 2017Date of Patent: February 4, 2020Assignees: STEMRIM INC., OSAKA UNIVERSITYInventors: Katsuto Tamai, Takehiko Yamazaki, Tsutomu Kanezaki, Shigeru Sakurai, Yukiko Noguchi, Mayumi Endo, Natsumi Hamabuchi, Kana Naito
-
Publication number: 20190358307Abstract: The purpose of the present invention is to provide a novel medicine that is effective in treating cerebral infarction. The present invention provides a pharmaceutical composition that contains a peptidyl-prolyl cis-trans isomerase B (PPIB) protein, a nucleic acid encoding the PPIB protein, or a cell that secretes the PPIB protein.Type: ApplicationFiled: November 9, 2017Publication date: November 28, 2019Applicants: STEMRIM INC., OSAKA UNIVERSITYInventors: Katsuto TAMAI, Takehiko YAMAZAKI, Koichi YOKOTA, Takahiro AOTO
-
Patent number: 10364276Abstract: (Objective) An objective of the present invention is to provide therapeutic agents that, in association with stimulation of PDGFR?-positive cells such as bone marrow mesenchymal stem cells, promote their mobilization into blood and accumulation in a damaged tissue, and induce tissue regeneration in a living body. (Means for solution) Multiple peptides were synthesized, and the migration-promoting activity of each peptide was evaluated. As a result, the present inventors successfully identified multiple peptides that have migration-promoting activity on a PDGFR?-positive bone marrow mesenchymal stem cell line (MSC-1). Further, the present inventors confirmed that the identified peptides also have migration-promoting activity on skin fibroblasts, which are PDGFR?-positive cells.Type: GrantFiled: April 3, 2012Date of Patent: July 30, 2019Assignees: STEMRIM INC., OSAKA UNIVERSITYInventors: Katsuto Tamai, Takehiko Yamazaki, Tsutomu Kanezaki, Shigeru Sakurai, Yukiko Noguchi, Mayumi Endo, Natsumi Hamabuchi, Kana Naito
-
Patent number: 10160792Abstract: (Objective) An objective of the present invention is to provide therapeutic agents that, in association with stimulation of PDGFR?-positive cells such as bone marrow mesenchymal stem cells, promote their mobilization into blood and accumulation in a damaged tissue, and induce tissue regeneration in a living body. (Means for solution) Multiple peptides were synthesized, and the migration-promoting activity of each peptide was evaluated. As a result, the present inventors successfully identified multiple peptides that have migration-promoting activity on a PDGFR?-positive bone marrow mesenchymal stem cell line (MSC-1). Further, the present inventors confirmed that the identified peptides also have migration-promoting activity on skin fibroblasts, which are PDGFR?-positive cells.Type: GrantFiled: April 3, 2012Date of Patent: December 25, 2018Assignees: STEMRIM INC., OSAKA UNIVERSITYInventors: Katsuto Tamai, Takehiko Yamazaki, Tsutomu Kanezaki, Shigeru Sakurai, Yukiko Noguchi, Mayumi Endo, Natsumi Hamabuchi, Kana Naito